TY - JOUR T1 - Correcting excess mortality for pandemic-associated population decreases JF - medRxiv DO - 10.1101/2021.02.10.21251461 SP - 2021.02.10.21251461 AU - Jeremy Samuel Faust AU - Chengan Du AU - Shu-Xia Li AU - Zhenqiu Lin AU - Harlan M. Krumholz Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/12/2021.02.10.21251461.abstract N2 - Objectives We identify a correction for excess mortality that takes the sudden unexpected changes in the size of the United States population into account.Design This is a weekly cross-sectional analysis of all-cause mortality since week 5, 2020. We describe and apply a simple correction that takes population changes into account in order to provide corrected weekly estimates of expected deaths for 2020 and 2021.Setting The United States.Participants All United States residents.Interventions The covid-19 pandemic.Main outcome measures Expected and excess mortality for the United States during the covid-19 period.Results As of week 53, 2020 (ending January 2, 2021), approximately >10,200 more excess deaths have occurred in the United States than could be detected if expected deaths projections were not amended to reflect population decreases during 2020. The figure is projected to rise to >12,600 (>600 weekly) by week 5, 2021. Assuming recent excess mortality and pandemic-associated visa reductions continue until the earliest time herd immunity could be approached resulting from a combination of infections and vaccinations (week 17, 2021), if point estimates of expected deaths are not corrected, expected deaths will be overestimated (and therefore potential excess mortality underestimated) by ∼43,000 during 2021, or >53,300 since the outbreak of the pandemic measurement period (beginning week 5, 2020). By late December 2021, weekly expected death differences are projected to approach 1,000 per week.Conclusions Current models measuring excess mortality should be revised immediately so that public health officials do not lose the ability to detect ongoing excess mortality as the population changes continue to compound, lowering the number of weekly expected deaths. A similar approach should be used in the middle and late phases of all future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study had no specific fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was not subject to institutional review because it relied solely upon data available to the public. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available to the public and were available to all authors at all times. ER -